CL2016001359A1 - Método para preparar una composición seca para inhalación en polvo que comprende un primer y segundo ingrediente activo en forma micronizada. - Google Patents

Método para preparar una composición seca para inhalación en polvo que comprende un primer y segundo ingrediente activo en forma micronizada.

Info

Publication number
CL2016001359A1
CL2016001359A1 CL2016001359A CL2016001359A CL2016001359A1 CL 2016001359 A1 CL2016001359 A1 CL 2016001359A1 CL 2016001359 A CL2016001359 A CL 2016001359A CL 2016001359 A CL2016001359 A CL 2016001359A CL 2016001359 A1 CL2016001359 A1 CL 2016001359A1
Authority
CL
Chile
Prior art keywords
active ingredient
preparing
particulate excipient
micronized form
mixing
Prior art date
Application number
CL2016001359A
Other languages
English (en)
Inventor
Terhi Mattila
Anita Happonen
Jussi Haikarainen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52146529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001359(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of CL2016001359A1 publication Critical patent/CL2016001359A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Método para preparar una composición seca para inhalación en polvo que comprende un primer y segundo ingrediente activo en forma micronizada que comprende las etapas de: (a) mezclar el primer ingrediente activo y una porción del segundo ingrediente activo con un primer excipiente en partículas que tiene un VMD dentro del intervalo de 30 a 70 ?m para proporcionar una primera premezcla; (b) mezclar la porción restante del segundo ingrediente activo con un segundo excipiente en partículas que tiene VMD dentro del intervalo de 80 a 150 ?m para proporcionar una segunda premezcla; y (c) mezclar juntas la primera y la segunda premezclas, opcionalmente con una porción adicional del primer o segundo excipiente en partículas, y (d) opcionalmente mezclar la mezcla obtenida en (c) con una porción adicional del primer o segundo excipiente en partículas; en donde el primer excipiente en partículas y el segundo excipiente en particulado es lactosa; en donde los ingredientes activos primero y segundo se seleccionan de esteroides antiinflamatorios y broncodilatadores; y en donde la cantidad de cada ingrediente activo está dentro del rango de 0,02% a 30% por peso de la composición.
CL2016001359A 2013-12-06 2016-06-03 Método para preparar una composición seca para inhalación en polvo que comprende un primer y segundo ingrediente activo en forma micronizada. CL2016001359A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361913024P 2013-12-06 2013-12-06

Publications (1)

Publication Number Publication Date
CL2016001359A1 true CL2016001359A1 (es) 2016-11-18

Family

ID=52146529

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001359A CL2016001359A1 (es) 2013-12-06 2016-06-03 Método para preparar una composición seca para inhalación en polvo que comprende un primer y segundo ingrediente activo en forma micronizada.

Country Status (26)

Country Link
EP (1) EP3076957B1 (es)
JP (1) JP6353049B2 (es)
KR (1) KR102255402B1 (es)
CN (2) CN113908142A (es)
AU (1) AU2014359111B2 (es)
BR (1) BR112016012871B1 (es)
CA (1) CA2928695C (es)
CL (1) CL2016001359A1 (es)
CY (1) CY1122797T1 (es)
DK (1) DK3076957T3 (es)
EA (1) EA033247B1 (es)
ES (1) ES2776350T3 (es)
HR (1) HRP20200618T1 (es)
HU (1) HUE049162T2 (es)
LT (1) LT3076957T (es)
MA (1) MA39089B1 (es)
MX (1) MX368857B (es)
MY (1) MY185073A (es)
PH (1) PH12016501045A1 (es)
PL (1) PL3076957T3 (es)
PT (1) PT3076957T (es)
SA (1) SA516371266B1 (es)
SI (1) SI3076957T1 (es)
UA (1) UA118861C2 (es)
WO (1) WO2015082756A1 (es)
ZA (1) ZA201602909B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015094625A1 (en) * 2013-12-20 2015-06-25 The Procter & Gamble Company Diaper with improved cuffs and fit
WO2024010539A1 (en) * 2022-07-07 2024-01-11 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation using different mixers
CN115364075B (zh) * 2022-09-16 2023-11-10 苏州易合医药有限公司 一种吸入颗粒组合物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
US6369115B1 (en) * 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
WO2003024396A2 (en) * 2001-09-17 2003-03-27 Glaxo Group Limited Dry powder medicament formulations
JP3691459B2 (ja) * 2002-06-14 2005-09-07 久光メディカル株式会社 粉末状吸入剤組成物
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
JP4744876B2 (ja) * 2002-08-21 2011-08-10 ノートン・ヘルスケアー リミテッド 乾燥粉末吸入組成物の製造方法
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
EP2221048A1 (en) * 2009-02-18 2010-08-25 Siegfried Generics International AG Pharmaceutical composition for inhalation
EP2571486A4 (en) * 2010-05-20 2013-12-04 Sun Pharma Advanced Res Co Ltd DRY POWDER INHALATION COMPOSITION
BR112014017481A8 (pt) * 2012-01-25 2021-06-15 Chiesi Farm Spa formulação em pó seco para uso em um inalador de pó seco, inalador de pó seco e uso de uma formulação

Also Published As

Publication number Publication date
DK3076957T3 (da) 2020-04-27
SA516371266B1 (ar) 2019-08-01
CN105873575A (zh) 2016-08-17
MA39089A1 (fr) 2017-10-31
KR20160093718A (ko) 2016-08-08
KR102255402B1 (ko) 2021-05-24
ZA201602909B (en) 2017-04-26
PH12016501045B1 (en) 2016-07-25
AU2014359111A1 (en) 2016-05-19
EA201691181A1 (ru) 2016-09-30
SI3076957T1 (sl) 2020-04-30
CA2928695A1 (en) 2015-06-11
CY1122797T1 (el) 2021-05-05
BR112016012871B1 (pt) 2022-10-11
NZ719346A (en) 2021-01-29
LT3076957T (lt) 2020-03-10
MA39089B1 (fr) 2019-03-29
PT3076957T (pt) 2020-03-05
HUE049162T2 (hu) 2020-09-28
WO2015082756A1 (en) 2015-06-11
CN113908142A (zh) 2022-01-11
HRP20200618T1 (hr) 2020-07-10
EA033247B1 (ru) 2019-09-30
ES2776350T3 (es) 2020-07-30
PL3076957T3 (pl) 2020-06-29
UA118861C2 (uk) 2019-03-25
PH12016501045A1 (en) 2016-07-25
BR112016012871A2 (pt) 2020-08-04
AU2014359111B2 (en) 2019-06-13
JP2016539151A (ja) 2016-12-15
MX2016007266A (es) 2016-09-07
EP3076957A1 (en) 2016-10-12
CA2928695C (en) 2022-03-29
MX368857B (es) 2019-10-18
EP3076957B1 (en) 2020-02-05
JP6353049B2 (ja) 2018-07-04
MY185073A (en) 2021-04-30

Similar Documents

Publication Publication Date Title
ECSP17007538A (es) 2-(morfolin-4-il)-1,7-naftiridinas
BR112016000937A8 (pt) formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
SV2016005236A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
DOP2016000047A (es) Compuestos y composiciones como inhibidores de la mek
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
TN2015000395A1 (en) Respirable agglomerates of porous carrier particles and micronized drug
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
ECSP16074478A (es) Compuestos novedosos
CO6920294A2 (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
PE20151759A1 (es) Imidazopiridazinas sustituidas
CL2016001359A1 (es) Método para preparar una composición seca para inhalación en polvo que comprende un primer y segundo ingrediente activo en forma micronizada.
BR112018072113A2 (pt) excipiente à base de proteínas para ingredientes farmacêuticos ativos
DOP2016000007A (es) Pirazolpiridinas sustituidas
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas
CO2017004504A2 (es) Composición que comprende al menos un polvo seco obtenido por secado por atomización para aumentar la estabilidad de la formulación
NI202000028A (es) Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112013017570A2 (pt) compostos de pirazola como antagonistas de crth2
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
BR112016014295A2 (pt) Composto; processo para a preparação de um composto; e composição farmacêutica compreendendo um composto
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
CO2018007610A2 (es) Derivados de indano y su uso en terapias
AR100625A1 (es) Formulación de ceritinib